Abstract
Castleman Disease (CMD) is a form of lymphoproliferative disorder that most commonly occurs in the mediastinum. CMD can involve a single lymph node (termed Unicentric CMD) or multiple lymph nodes (termed Multicentric CMD). Only 55 cases of CMD with mesenteric involvement have been described in the medical literature. Variable symptoms and physical findings are present. Diagnosis is based on characteristic findings on imaging studies. Suggested treatments include surgical resection, corticosteroids, chemotherapy and inhibitors of interleukin-6 (IL-6) and are tailored to individual cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Suggested Reading
Bracale U, Pacelli F, Milone M, et al. Laparoscopic treatment of abdominal unicentric castleman’s disease: a case report and literature review. BMC Surg. 2017;17(1):38.
Lv A, Hao C, Qian H, Leng J, Liu W. Castleman disease of the mesentery as the great mimic: incidental finding of one case and the literature review. BioScience Trends. 2015;9(3):198–202.
Dei-Adomakoh YA, Quarcoopome L, Abrahams AD, Segbefia CI, Dey DI. Sjögren’s and plasma cell variant Castleman disease: a case report. Ghana Med J. 2018;52(1):61–5.
Papaziogas B, Chatzimavroudis G, Koutelidakis I, Grigoriou M, Atmatzidis K. A rare form of isolated mesenteric Castleman’s disease presenting as an abdominal mass (isolated mesenteric Castleman’s disease). J Gastrointestin Liver Dis. 2006;15(2):171–4.
Caroline Ribeiro Sales A, Romão de Souza Junior V, Iglis de Oliveira M, Azevedo Braga Albuquerque C, de Barros Campelo Júnior E, Sérgio Ramos de Araújo P. Multicentric Castleman’s disease in human immunodeficiency virus infection: two case reports. J Med Case Rep. 2018;12(1):117.
Yoshizaki K, Murayama S, Ito H, Koga T. The role of interleukin-6 in Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):23–36.
van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):89–106.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, et al. Siltuximab for multicentric Castleman’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–74.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ehrenpreis, E.D. (2021). Castleman Disease with Mesenteric Involvement. In: Ehrenpreis, E.D., Alverdy, J.C., Wexner, S.D. (eds) The Mesenteric Organ in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-71963-0_34
Download citation
DOI: https://doi.org/10.1007/978-3-030-71963-0_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71962-3
Online ISBN: 978-3-030-71963-0
eBook Packages: MedicineMedicine (R0)